<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613067</url>
  </required_header>
  <id_info>
    <org_study_id>IB-0709-053</org_study_id>
    <nct_id>NCT00613067</nct_id>
  </id_info>
  <brief_title>ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder</brief_title>
  <acronym>N1</acronym>
  <official_title>The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone
      intensities have been suggested as a correlative of central serotonergic activity. A strong
      loudness dependence amplitude increase (strong intensity dependence) reflects low
      serotonergic neurotransmission and vice versa. Many researchers assumed that the brain
      serotonergic activity could influence treatment response of highly selective serotonin
      reuptake inhibitors in depression and anxiety disorders. There are a couple of studies
      reporting associations of N1 amplitude intensity dependence with response to Citalopram
      (positive correlation) and Reboxetine (negative correlation) treatment in major depressive
      disorder patients. But so far there have been no reports about associations between ERP N1
      and antidepressant response in GAD patients.

      So, it would be very interesting to explore the correlations between ERP N1 amplitude change
      and the Escitalopram treatment responsiveness in GAD patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event related potential (ERP) N100</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- HAMA - HAMD - CGI - Beck Anxiety Inventory(self rating)</measure>
    <time_frame>baseline, 2, 4, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>GAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 patients with Generalized Anxiety disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>Start with escitalopram 10mg
According to patient's symptoms, stay on 10mg or increase up to 20mg
Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages
Length of washout period will be at least 2 weeks for any psychotropic drugs</description>
    <arm_group_label>GAD</arm_group_label>
    <other_name>lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV TR for GAD

          -  Hamilton Rating Scale for Anxiety (HAMA) &gt;18

          -  18 to 75 years old

        Exclusion Criteria:

          -  Severe medical illness

          -  Other psychiatric illness

          -  HAMD &gt; 18

          -  High suicidal risk

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Hwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatry department, Inje Univ. Ilsanpaik Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Min Park, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatry department, Inje Univ. Ilsanpaik Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Man Bae, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatry department, Inje Univ. Ilsanpaik Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatry department, Inje Univ. Ilsanpaik Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Kyunggi</state>
        <zip>414-410</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ceclab.re.kr/index.asp</url>
  </link>
  <results_reference>
    <citation>Linka T, Müller BW, Bender S, Sartory G, Gastpar M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry. 2005 May;38(3):139-43.</citation>
    <PMID>15902586</PMID>
  </results_reference>
  <results_reference>
    <citation>Linka T, Sartory G, Bender S, Gastpar M, Müller BW. The intensity dependence of auditory ERP components in unmedicated patients with major depression and healthy controls. An analysis of group differences. J Affect Disord. 2007 Nov;103(1-3):139-45. Epub 2007 Feb 20.</citation>
    <PMID>17316822</PMID>
  </results_reference>
  <results_reference>
    <citation>Linka T, Müller BW, Bender S, Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett. 2004 Sep 9;367(3):375-8.</citation>
    <PMID>15337269</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seung-Hwan Lee</name_title>
    <organization>Department of Psychiatry, Inje Univ. Ilsanpaik Hospital</organization>
  </responsible_party>
  <keyword>Generalized anxiety disorder</keyword>
  <keyword>N100</keyword>
  <keyword>Central serotonergic activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 24, 2011</submitted>
    <returned>July 21, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

